image
Healthcare - Medical - Distribution - NASDAQ - US
$ 2.4
-10.8 %
$ 72.6 M
Market Cap
-10.0
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one ZYXI stock under the worst case scenario is HIDDEN Compared to the current market price of 2.4 USD, Zynex, Inc. is HIDDEN

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one ZYXI stock under the base case scenario is HIDDEN Compared to the current market price of 2.4 USD, Zynex, Inc. is HIDDEN

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one ZYXI stock under the best case scenario is HIDDEN Compared to the current market price of 2.4 USD, Zynex, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart ZYXI

image
$9.0$9.0$8.0$8.0$7.0$7.0$6.0$6.0$5.0$5.0$4.0$4.0$3.0$3.0$2.0$2.0$1.0$1.015 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 JunJul '25Jul '25
FINANCIALS
192 M REVENUE
4.36%
5.99 M OPERATING INCOME
-44.43%
2.99 M NET INCOME
-69.24%
12.7 M OPERATING CASH FLOW
-28.36%
-578 K INVESTING CASH FLOW
40.17%
-17.1 M FINANCING CASH FLOW
-223.56%
26.6 M REVENUE
-42.19%
-13.1 M OPERATING INCOME
-2226.29%
-10.4 M NET INCOME
-1590.41%
-10.5 M OPERATING CASH FLOW
-429.57%
-168 K INVESTING CASH FLOW
22.22%
-5.11 M FINANCING CASH FLOW
-2140.35%
Balance Sheet Zynex, Inc.
image
Current Assets 75.2 M
Cash & Short-Term Investments 39.6 M
Receivables 18 M
Other Current Assets 17.5 M
Non-Current Assets 46.9 M
Long-Term Investments 0
PP&E 12.9 M
Other Non-Current Assets 34 M
32.46 %14.76 %14.36 %10.57 %27.85 %Total Assets$122.1m
Current Liabilities 16.9 M
Accounts Payable 7.09 M
Short-Term Debt 0
Other Current Liabilities 9.77 M
Non-Current Liabilities 69.5 M
Long-Term Debt 58.6 M
Other Non-Current Liabilities 10.9 M
8.21 %11.32 %67.81 %12.67 %Total Liabilities$86.4m
EFFICIENCY
Earnings Waterfall Zynex, Inc.
image
Revenue 192 M
Cost Of Revenue 39.4 M
Gross Profit 153 M
Operating Expenses 147 M
Operating Income 5.99 M
Other Expenses 3 M
Net Income 2.99 M
200m200m180m180m160m160m140m140m120m120m100m100m80m80m60m60m40m40m20m20m00192m(39m)153m(147m)6m(3m)3mRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
79.50% GROSS MARGIN
79.50%
3.11% OPERATING MARGIN
3.11%
1.56% NET MARGIN
1.56%
8.38% ROE
8.38%
2.45% ROA
2.45%
4.70% ROIC
4.70%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Zynex, Inc.
image
18m18m16m16m14m14m12m12m10m10m8m8m6m6m4m4m2m2m00(2m)(2m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income 2.99 M
Depreciation & Amortization 4.78 M
Capital Expenditures -578 K
Stock-Based Compensation 2.99 M
Change in Working Capital 0
Others 2.89 M
Free Cash Flow 12.1 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Zynex, Inc.
image
Wall Street analysts predict an average 1-year price target for ZYXI of $13.2 , with forecasts ranging from a low of $11 to a high of $16 .
ZYXI Lowest Price Target Wall Street Target
11 USD 358.33%
ZYXI Average Price Target Wall Street Target
13.2 USD 448.61%
ZYXI Highest Price Target Wall Street Target
16 USD 566.67%
Price
Max Price Target
Min Price Target
Average Price Target
16161414121210108866442200Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26Jul '26Jul '26
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0.0909 USD DIVIDEND PER SHARE
Q1
Q2
Q3
Q4
0.160000000.160000000.140000000.140000000.120000000.120000000.100000000.100000000.080000000.080000000.060000000.060000000.040000000.040000000.020000000.020000000.000000000.000000000.0909090.063636370.150.002018201820222022
Download SVG
Download PNG
Download CSV
5. COMPETITION
slide 2 of 8
6. Ownership
Insider Ownership Zynex, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
148 K USD 1
6-9 MONTHS
455 K USD 2
9-12 MONTHS
323 K USD 2
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
58.2 K USD 1
9-12 MONTHS
7. News
Zynex CEO Thomas Sandgaard discusses leadership transition - ICYMI Zynex Inc (NASDAQ:ZYXI) CEO Thomas Sandgaard talked with Proactive about his decision to step down from his position after nearly three decades leading the medical device company. He described the challenges of starting a company with no funding, navigating public listings, and expanding operations to help over a million patients manage pain. proactiveinvestors.com - 1 week ago
Tricare Temporary Payment Suspension Update ENGLEWOOD, Colo. , July 2, 2025 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced the Company received an update from Tricare that the temporary payment suspension will continue. prnewswire.com - 2 weeks ago
Zynex taps Steve Dyson as chief executive officer Zynex Inc (NASDAQ:ZYXI) has announced the appointment of Steve Dyson as chief executive officer, marking a new chapter for the medical technology company founded in 1996 by its outgoing CEO Thomas Sandgaard.  Sandgaard will continue to serve as chairman of the board and will also lead the company's Technology Committee. proactiveinvestors.com - 2 weeks ago
Zynex Announces Steven Dyson as New CEO ENGLEWOOD, Colo. , June 30, 2025 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in noninvasive medical devices for pain management, rehabilitation, and patient monitoring, today announced the appointment of Steven Dyson as Chief Executive Officer. prnewswire.com - 2 weeks ago
Zynex awarded UK patent for non-invasive sepsis monitoring technology Zynex Inc (NASDAQ:ZYXI) announced that it has been issued a UK patent for its multiparameter, non-invasive sepsis monitor. The company highlighted that its patented technology is designed to continuously track multiple physiological signals with the goal of providing early alerts on patient trends and potential sepsis development. proactiveinvestors.com - 3 weeks ago
Zynex Announces Award of UK Patent for Non-Invasive Detection of Sepsis ENGLEWOOD, Colo. , June 25, 2025 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of noninvasive medical devices for pain management, rehabilitation, and patient monitoring, today announced it has been awarded UK patent 2617515 for a multiparameter, noninvasive sepsis monitor. prnewswire.com - 3 weeks ago
Lost Money on Zynex, Inc. (ZYXI)? Contact Levi & Korsinsky Before May 19, 2025 to Join Class Action NEW YORK, NY / ACCESS Newswire / May 19, 2025 / If you suffered a loss on your Zynex, Inc. (NASDAQ:ZYXI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/zynex-inc-lawsuit-submission-form?prid=149275&wire=1&utm_campaign=12 or contact Joseph E. Levi, Esq. accessnewswire.com - 1 month ago
Zynex, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses; May 19, 2025 Deadline to file Lead Plaintiff Motion Investors can contact the law firm at no cost to learn more about recovering their losses globenewswire.com - 1 month ago
ZYXI Deadline: ZYXI Investors with Losses in Excess of $100K Have Opportunity to Lead Zynex, Inc. Securities Fraud Lawsuit NEW YORK , May 19, 2025 /PRNewswire/ --  Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Zynex, Inc. (NASDAQ: ZYXI) between March 13, 2023 and March 11, 2025, both dates inclusive (the "Class Period"), of the important May 19, 2025 lead plaintiff deadline. So What: If you purchased Zynex securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. prnewswire.com - 1 month ago
ZYXI LAWSUIT ALERT: Levi & Korsinsky Notifies Zynex, Inc. Investors - Lead Plaintiff Deadline May 19, 2025 NEW YORK, NY / ACCESS Newswire / May 19, 2025 / If you suffered a loss on your Zynex, Inc. (NASDAQ:ZYXI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/zynex-inc-lawsuit-submission-form?prid=149257&wire=1&utm_campaign=7 or contact Joseph E. Levi, Esq. accessnewswire.com - 1 month ago
ZYXI Investors Have Opportunity to Lead Zynex, Inc. Securities Fraud Lawsuit with the Schall Law Firm LOS ANGELES--(BUSINESS WIRE)--ZYXI Investors Have Opportunity to Lead Zynex, Inc. Securities Fraud Lawsuit with the Schall Law Firm. businesswire.com - 1 month ago
ZYXI INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Zynex, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit NEW YORK, May 19, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Zynex, Inc. (“Zynex” or “the Company”) (NASDAQ: ZYXI) and certain of its officers. globenewswire.com - 1 month ago
8. Profile Summary

Zynex, Inc. ZYXI

image
COUNTRY US
INDUSTRY Medical - Distribution
MARKET CAP $ 72.6 M
Dividend Yield 0.00%
Description Zynex, Inc., through its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography triggered electrical stimulation device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; and E-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body, and batteries for use in electrotherapy products. In addition, the company distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, LSO Back Braces for lumbar support, and knee braces for knee support. Further, it offers Zynex Fluid Monitoring System (CM-1500), a fluid volume monitor, which is a non-invasive medical device for monitoring relative fluid volume changes used in operating and recovery rooms to detect fluid loss during surgery and internal bleeding during recovery; Zynex Wireless Fluid Monitoring System (CM-1600), a noninvasive monitoring device designed to measure relative changes in fluid volume in adult patients; NiCO CO-Oximeter, a laser-based noninvasive co-oximeter; and HemeOx tHb Oximeter, a laser-based total hemoglobin pulse oximeter. The company provides its products for use in pain management and control; stroke and spinal cord injury rehabilitation; hemodynamic monitoring; and pulse oximetry monitoring. It sells its products through direct sales force primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado.
Contact 9655 Maroon Circle, Englewood, CO, 80112 https://www.zynex.com
IPO Date Feb. 25, 2004
Employees 1000
Officers Mr. Neil Friery Chief Operating Officer of Zynex Monitoring Solutions, Inc. Mr. Steve Fox Executive Vice President of Sales Mr. Thomas Sandgaard Founder, President, Chief Executive Officer & Chairman Mr. Daniel J. Moorhead CPA Chief Financial Officer Ms. Anna Lucsok Chief Operating Officer Mr. Donald Gregg President of Zynex Monitoring Solutions